Vault-13

SR One Capital Management, LP

Redwood City, CA · CIK 1910264 · 13F filing filed 2026-08-12

SEC-registered investment adviser since 2020 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Redwood City, CA (main office)United States United Statesabout 10
LondonUnited Kingdom United Kingdom5

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$1.0bn reported value +13.5% vs Q1 2026
15positions
95.1%in top 10
3 new 1 added 0 reduced 2 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 VERADERMICS INC COMMON STOCK MANE MANE 2,401,868 $295.3m28.42% 28.42% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 2.4m, Q2 2026 2.4m
2 ZENAS BIOPHARMA INC COM ZBIO ZBIO 5,037,854 $127.9m12.31% 12.31% UnchangedShares held: Q3 2025 4.9m, Q4 2025 5.0m, Q1 2026 5.0m, Q2 2026 5.0m
3 CRISPR THERAPEUTICS AG NAMEN AKT CRSP CRSP 2,038,763 $111.2m10.70% 10.70% UnchangedShares held: Q3 2025 2.0m, Q4 2025 2.0m, Q1 2026 2.0m, Q2 2026 2.0m
4 AVALYN PHARMACEUTICALS INC COM SHS AVLN AVLN 3,308,649 $108.9m10.48% 10.48% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 3.3m
5 DESIGN THERAPEUTICS INC COM DSGN DSGN 6,526,476 $94.4m9.09% 9.09% UnchangedShares held: Q3 2025 6.5m, Q4 2025 6.5m, Q1 2026 6.5m, Q2 2026 6.5m
6 ODYSSEY THERAPEUTICS INC COMMON STOCK ODTX ODTX 3,794,883 $71.0m6.83% 6.83% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 3.8m
7 ALUMIS INC COM ALMS ALMS 1,959,896 $55.2m5.31% 5.31% UnchangedShares held: Q3 2025 2.0m, Q4 2025 2.0m, Q1 2026 2.0m, Q2 2026 2.0m
8 ORIC PHARMACEUTICALS INC COM ORIC ORIC 4,615,384 $50.0m4.81% 4.81% AddedShares held: Q3 2025 4.5m, Q4 2025 4.5m, Q1 2026 4.5m, Q2 2026 4.6m +100.5k +100,455 2.2%
9 MINERALYS THERAPEUTICS INC COM MLYS MLYS 1,563,966 $42.2m4.06% 4.06% UnchangedShares held: Q3 2025 2.1m, Q4 2025 1.6m, Q1 2026 1.6m, Q2 2026 1.6m
10 ARS PHARMACEUTICALS INC COM SPRY SPRY 4,012,903 $32.1m3.09% 3.09% UnchangedShares held: Q3 2025 4.0m, Q4 2025 4.0m, Q1 2026 4.0m, Q2 2026 4.0m
11 MOBIA MED INC COMMON STOCK MOBI MOBI 1,986,072 $26.6m2.56% 2.56% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 2.0m
12 NKARTA INC COM NKTX NKTX 3,333,333 $9.4m0.91% 0.91% UnchangedShares held: Q3 2025 3.3m, Q4 2025 3.3m, Q1 2026 3.3m, Q2 2026 3.3m
13 OCULIS HOLDING AG ORDINARY SHARES OCS OCS 641,022 $8.9m0.86% 0.86% UnchangedShares held: Q3 2025 322.5k, Q4 2025 641.0k, Q1 2026 641.0k, Q2 2026 641.0k
14 ULTRAGENYX PHARMACEUTICAL IN COM RARE RARE 137,753 $4.6m0.44% 0.44% UnchangedShares held: Q3 2025 0, Q4 2025 137.8k, Q1 2026 137.8k, Q2 2026 137.8k
15 ENGENE HOLDINGS INC COM COM 747,750 $1.3m0.12% 0.12% UnchangedShares held: Q3 2025 747.8k, Q4 2025 747.8k, Q1 2026 747.8k, Q2 2026 747.8k

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
ARCELLX INC ACLX ACLX 2,346,630 $269.4m2.3m shares
ORUKA THERAPEUTICS INC ORKA ORKA 430,330 $21.1m430.3k shares